Percentage of female patients aged 18 to 44 years and all men aged 18 years and older with a diagnosis chronic hepatitis C who are receiving antiviral treatment who were counseled regarding contraception prior to the initiation of antiviral treatment
This measure identifies the percentage of patients with chronic Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV Viral Load testing 6 months prior to initiation of antiviral therapy.
The percentage of patients aged 2 through 64 with a high risk condition, or aged 65 years and older who either received a pneumococcal vaccine (reported separately) or had a contraindication to pneumococcal vaccine (reported separately).
In-hospital deaths per 1,000 hospital discharges with hip fracture as a principal diagnosis for patients ages 65 years and older. Excludes periprosthetic fracture discharges, obstetric discharges, cases in hospice care at admission, and transfers to another hospital.
[NOTE: The software provides the rate per hospital discharge. However, common practice reports the measure as per 1,000 discharges. The user must multiply the rate obtained from the software by 1,000 to report in-hospital deaths per 1,000 hospital discharges.]
The percentage of women with a history of breast cancer treated with curative intent who had breast cancer surveillance for local regional recurrence (LRR)annually.
The percentage of men with definitively treated localized prostate cancer who had at least one PSA level in the past 12 months.
To ensure that members diagnosed or seeking treatment for sexually transmitted diseases be screened for HIV.
Percentage of patients with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit: aged 13 years and older who have a history of a CD4 count less than or equal to 500 cells/mm3; aged 13 years and older who have a history of an AIDS-defining illness, regardless of CD4 count; or who are pregnant, regardless of CD4 count or age, who were prescribed potent antiretroviral therapy
Percentage of patients aged six months and older with a diagnosis of HIV/AIDS, who have received at least one hepatitis B vaccination, or who have documented immunity
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who had at least two medical visits during the measurement year, with at least 90 days between each visit, who are receiving potent antiretroviral therapy*, who have a viral load <200 copies/mL after at least 6 months of potent antiretroviral therapy*
*Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trials